This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Amiral, J. Search for Related Content PubMed Articles by Amiral, J. Social Bookmarking                         What's this?

State-of-the-Art Review: Molecular Markers in Thrombosis and Hemostasis

Serbio Research Laboratory, Gennevilliers, France

Molecular markers for exploring the different stages of hemostasis activation are now available. These markers allow investigation of endothelial functions, blood cell activation, stimulation of coagulation pathways, involvement of the fibrinolytic system, and profiling of the coagulolytic-equilibrium that regulates hemostasis. Additionally, these markers find useful applications for monitoring therapies, following-up clinical states associated with high thrombotic risk, and validating new drugs and analyzing their mode of action. Furthermore, these markers may allow for recognition of the evolution of early disease in the clinically silent phase. Large scale epidemiological and longitudinal studies are required for establishing this latter approach. Up to now, only D. Dimer is used in routine clinical application for exclusion diagnosis of deep-veinous-thrombosis and pulmonary embolism. Other markers must prove their sensitivity for the early asymptomatic period and demonstrate their applicability throughout disease evolution. According to pathology and application, different markers may provide complementary information. Some markers, e.g., D. Dimer, soluble thrombomodulin, and modified AT-III (ATM), are used on standard citrated plasma samples. Modem and flexible technologies are now available for point-of-care testing (when required), quick and sensitive measurements in emergency conditions, and full automation when necessary. Lastly, factors that trigger hemostatic activation can now be evaluated and provide information on etiology. In this latter respect, autoimmunity may be important in thrombotic disease induction. Key Words: Hemostatic activation—Molecular markers— Thrombosis—Predictivity—Monitoring antithrombotic therapies.

Clinical and Applied Thrombosis/Hemostasis, Vol. 3, No. 2, 71-81 (1997)
DOI: 10.1177/107602969700300201


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?